Jazz Pharmaceuticals

Recent news

• Rating change
  Morgan Stanley Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $283
  Market Newswire · 2026/8/13
• Rating change
  A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $283 to $315
  Market Newswire · 2026/8/12
• Company notice
  Shanghai Sanyou Medical Co., Ltd: Voluntary Disclosure Notice on the JAZZ System, a spinal fixed connector system, obtained a medical device registration certificate
  SZSI · 2025/7/16
• Company notice
  Jazz Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Cook Jennifer E.
  SEC · 2025/8/12
• Company notice
  Jazz Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(9.5%)
  SEC · 2024/11/13
• Company notice
  Jazz Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(9.5%)
  SEC · 2024/10/22
• Company notice
  Jazz Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Cook Jennifer E.
  SEC · 2024/8/7
• UBS Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $337
  Market Newswire · 2026/9/14
• Rating change
  A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $281 to $322
  Market Newswire · 2026/8/27
• Rating change
  TD Cowen Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $300
  Market Newswire · 2026/9/1
• Rating change
  Truist Financial Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating
  Market Newswire · 2026/9/1
• Rating change
  CCORF Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $300
  Market Newswire · 2026/9/1
• Rating change
  RBC Capital Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Raises Target Price to $299
  Market Newswire · 2026/8/28
• Rating change
  Barclays Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Raises Target Price to $271
  Market Newswire · 2026/9/10
• Rating change
  Needham Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $310
  Market Newswire · 2026/8/31
• Piper Sandler Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $310
  Market Newswire · 2026/9/28
• Citi Initiates Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Announces Target Price $325
  Market Newswire · 2026/9/30
• Goldman Sachs Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Raises Target Price to $337
  Market Newswire · 2026/9/24
• UBS Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Raises Target Price to $337
  Market Newswire · 2026/9/11
• Rating change
  A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $273 to $307
  Market Newswire · 2026/8/11

Headlines are aggregated automatically and are not independently verified or edited by our team.